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OPEN LETTER
Biomedicine, self and society: An agenda for collaboration and
 engagement [version 1; referees: 2 approved]
Martyn Pickersgill ,         Sarah Chan, Gill Haddow, Graeme Laurie, Devi Sridhar ,
 Steve Sturdy, Sarah Cunningham-Burley
Centre for Biomedicine, Self and Society, University of Edinburgh, Edinburgh, UK
Abstract
The commitment of massive resources – financial, social, organisational, and
human – drives developments in biomedicine. Fundamental transformations in
the generation and application of knowledge are challenging our
understandings and experiences of health, illness, and disease as well as the
organisation of research and care. Coupled with the accelerated pace of
change, it is pressing that we build authentic collaborations across and
between the biomedical sciences, humanities and social sciences, and wider
society. It is only in this way that we can ask and answer the penetrating
questions that will shape improvements in human health now and in the
decades ahead. We delineate the need for such commitments across five key
areas of human and societal experience that impact on and are impacted by
developments in biomedicine: disease; bodies; global movements and
institutions; law; and, science-society engagements. Interactions between
ideas, researchers, and communities across and within these domains can
provide a way into creating the new knowledges, methods, and partnerships
we believe are essential if the promises of biomedicine are to be realised.
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Introduction
Promise of new knowledge of health and disease and new means 
of preventing and treating illness—as well as the economic and 
commercial benefits such innovations might bring—animates 
biomedicine from top to bottom: from government policy mak-
ers and public and private funders, to individual doctors and 
researchers. In short, promise underpins the massive commit-
ment of resources—financial, social, organisational, human—that 
drives biomedicine (Brown & Michael, 2003). With such enor-
mous resources in play, it is unsurprising that developments in 
biomedicine are having a profound impact across many areas of 
human life and experience, the dynamics of which need urgent and 
rigorous attention (Rose, 2007). What biomedicine delivers is not 
always the same as what it promises: it is often only with the 
wisdom of hindsight that we are able to separate promise 
from what seems like inevitable hype (Feiler et al., 2017). An 
enterprise as vast as biomedicine is bound up with multiple, 
and often conflicting institutions and interests, which pull it in 
different directions; research and development rarely progress 
in a straight line, and innovation is fraught with unintended con-
sequences. Small wonder, then, if the outcomes of biomedical 
investment often differ from what was promised, with 
implications for society that go far beyond simply delivering 
new means of prevention and treatment.
The difficulty in foreseeing exactly how local, national, and glo-
bal biomedical initiatives will pan out is not a reason for resigned 
acceptance of whatever those programmes deliver, however. On 
the contrary, it underscores the need for close and continuing 
societal engagement and involvement with biomedicine, from 
the initial formulation of promising research programmes, right 
through to the design and implementation of new health inter-
ventions, and at all stages in between. Efforts to promote such 
engagement and involvement are still in their infancy, and it 
is far from clear what forms they might ultimately take and 
how they might influence innovation trajectories and health experi-
ences. Yet, if biomedicine is to develop in ways that respond most 
effectively to wider societal needs, it is imperative that such efforts 
continue in a spirit of open-minded collaboration and informed 
critical reflection.
As growing numbers of scientists and clinicians, funders and 
policy makers recognise, researchers in the social sciences and 
humanities possess knowledge and skills that equip them to 
play an invaluable role in informing, facilitating, and critiquing 
these endeavours (Pickersgill et al., 2018). Hence, for instance, 
the Wellcome Trust’s own commitment to fund research in the 
humanities and social sciences, “to bring new perspectives and 
ways of thinking to the historical, ethical and cultural contexts in 
which medical science takes place” (Wellcome Trust, 2010, p. 17). 
Likewise, the increasingly common practice of inviting social 
scientists and humanities scholars to participate in technosci-
entific projects, especially but not only in biomedicine, with the 
aim of securing improved governance and social acceptability. 
Yet, such collaborations bring novel challenges, as participants 
from within and across different disciplines try to work out 
their respective roles in the business of shaping techno-
science (Balmer et al., 2016; Callard & Fitzgerald, 2015; Frickel 
et al., 2016). Still, the need for such collaborations is para-
mount: biomedicine is reshaping our lives in multifaceted 
ways, through interrelated transformations of knowledge and 
practice, research and care, institutions and forms of govern-
ance, and individual and collective identities. Only by working 
across disciplinary boundaries, and with patients and publics, 
can we begin to comprehend these transformations in all their 
complexity, in ways that will enable us to engage constructively 
as well as critically with the dynamic relationships between 
science, public health, and healthcare; the shifting geographies of 
global, national, and local institutions; and the lived experiences 
of individuals and social groups around the world.
Transformations of biomedicine, self and society
There can be no simple prescription for how to build such 
collaborations, but we can at least begin to map the kinds of 
questions and issues they might most fruitfully seek to address. 
Social scientific and humanities research into the socio-cultural 
system that is biomedicine has already produced a wealth of 
insights into the nature and meaning of biomedical science and 
healthcare in societies. Drawing on such work, we can identify five 
interconnecting domains of individual and societal experience 
which provide fertile ground on which to cultivate new inter- and 
transdisciplinary enquiry. We now reflect on these and some of 
the issues they bring into focus.
Disease
Contemporary developments in biomedicine not only challenge 
long-accepted ideas about the nature of particular diseases; they 
also raise more general questions about just what counts as dis-
ease. This has enormous implications also for the organisation 
and delivery of health care, and for the sociotechnical organi-
sation of biomedical science, it will have profound impact on 
individuals’ experience of health and illness. In the case of 
cancer, for instance, increasingly ‘personalised’ understand-
ings of tumour aetiology are fragmenting existing classifica-
tory schemes and exacerbating clinical uncertainty, even as they 
offer the hope of new and more effective treatments (Keating & 
Cambrosio, 2011; Kerr & Cunningham-Burley, 2015). At the 
same time, population research into biomarkers in cancer and 
other conditions is leading to new categories of pre-disease risk, 
bringing new classes of ‘patients-in-waiting’ under medical 
management (Aronowitz, 2015; Timmermans & Buchbinder, 
2010). In psychiatry, the objectivity of established clinical tools 
for diagnosing mental disorders is being questioned by research 
funders, and there are calls for fundamental revision of existing 
diagnostic categories in the hope of driving therapeutic innova-
tion for mental ill-health (Pickersgill, 2014). Multi-dimensional 
approaches to population studies of experiences associated with 
psychiatric disorder are complicating understandings of the 
boundaries between normality and pathology. In society more 
widely, debates over disability, normalcy, ‘naturalness’ and 
enhancement further problematize concepts of disease and 
therapy, across a range of contexts spanning mental, physical 
and reproductive health and biomedicine (Nuffield Council on 
Bioethics, 2015). Meanwhile increasing costs, earlier preventive 
interventions and an ever-widening range of ways in which 
Page 2 of 10
Wellcome Open Research 2019, 4:9 Last updated: 06 FEB 2019
individuals seek to access biomedical technologies only add 
to the uncertainties about what counts as health, illness, and 
disease, and who benefits or suffers from those designations.
Together, these developments raise fundamental questions about 
the nature of disease, about who has the epistemic authority to 
label it as such, and about the normative and political significance 
of the disease concept itself. Biomedical research alone can-
not answer these questions; indeed, as the relationship between 
research and clinical practice becomes increasingly blurred, 
the issues only become more complex. Close engagement with 
social science and humanities research, as well as patients and 
their families, will help us all to navigate the fraught borderlands 
between health, illness, and disease in ways that best address 
the needs of individuals and populations.
Bodies
As a key site of biomedical intervention, the human body is 
increasingly chemically regulated, technologically augmented, 
and digitally rendered. The diverse connections between individu-
als and bodies and body-parts is intensely mediated by technical, 
social, and legal instruments (Crawford, 2014; Flear et al., 2013; 
Hoeyer, 2013; Mol, 2008; Quigley, 2018). In the case of 
emerging innovations such as 3D bioprinting of replacement 
organs, for instance, this raises questions around justice, social 
stratification, and regulation (Vermeulen et al., 2017). Other 
technoscientific developments in genetics and genomics, phar-
maceuticals, nanotechnology, and biotechnological devices have 
implications for individual experience and collective representa-
tions of embodiment. The changing relationship between sub-
jectivity and bodily identity and integrity potentially destabilises 
established ontologies of human beings. New vulnerabilities 
are created (Oudshoorn, 2016), contributing to a unique form of 
‘biomedical nemesis’ (Haddow, forthcoming; cf. Illich, 1974). 
Simultaneously, practices such as ‘biohacking’ and the ‘DIY Bio’ 
movement challenge who should be permitted to create hybrid 
artificial-organic bodies and techno-scientific identities, pushing 
the limits of current medical and legal understandings of con-
trol and responsibility. The increased datafication of the human 
body is arguably reducing aspects of the physical human form 
to inexhaustible datasets (Parry & Greenhough, 2017), signal-
ling the prospect of data flowing freely within and beyond the 
biomedical sphere, amplifying social and ethical concerns around 
the privacy and security of individuals, groups, and populations 
(Pink & Lanzeni, 2018).
Research in the social sciences and humanities provides a rich 
legacy of concepts and methods for understanding and access-
ing human embodied experience, challenging the mind-body 
dualism once inherent to ‘Western’ medicine. Contemporary 
research is beginning to shed light on how the possibilities of 
bodily repair, replacement and regeneration affect the ways in 
which individuals experience themselves as embodied beings. 
Fundamental questions about why changes to the material-
ity of the body alter subjectivity are brought into sharper relief 
(Haddow et al., 2015). We need such forms of interdiscipli-
nary research to apprehend fully the complexities of radical 
amelioration and enhancement (Pickersgill & Hogle, 2015). 
Careful and critical thinking with scientific researchers and 
clinical practitioners about how biomedical expertise and experts 
themselves (actively or otherwise) are informing and structuring 
shifting meanings and, indeed, what counts as embodied experi-
ence, is required.
Global movements and institutions
Accelerating global movements of people, goods, data, and 
capital have led to new geographies, both of health, illness, 
and disability, and of technoscientific practice (Bozorgmehr, 
2010; Keane, 1998). Despite commitments to globalisation and 
increased investments worldwide, the uneven spatial and socioeco-
nomic distribution of disease and ill-health continues (Clinton & 
Sridhar, 2017). With an exponential increase in funding for 
global health initiatives, and the creation of a global health 
technocracy, local concerns are increasingly over-written by 
transnational flows of ideas and resources, especially in low and 
middle income countries (Adams, 2016). Health priorities and 
practices are typically constructed through universalistic discourses 
of science and economics (Sridhar, 2011), ascribing value to indi-
viduals and their bodies and calculating the impact of disease 
in ways that elide local meanings, needs, and values (Anand 
et al., 2004; Leach & Tedros, 2014).
Models such as the Global Burden of Disease project funded 
by the Bill and Melinda Gates Foundation mediate the traffic 
between local and global understandings of disease. We need 
to critically interrogate the relevance and limitations of such 
models for priority-setting in health policy. At the same time, there 
is a too common tendency to frame financially poorer nations 
solely as beneficiaries of healthcare knowledge, as opposed to 
producers of it (White et al., 2014). Without attention to the dif-
ferent roles that low income countries can, should, and do play 
with respect to the production of biomedical and other health-
related knowledges and the actualization of new biotechnologies, 
we may fail to confront the problems of global scientific 
as well as health justice (Chan et al., 2017). Novel, spatial 
analyses of contemporary biomedicine must be attentive to the 
consequences of its glocalization (Robertson, 2012)—the ways in 
which biomedical ideas, actions, and artefacts not only circu-
late internationally, but are simultaneously localised and par-
ticularised. In so doing, they also need to break away from path-
dependent normative and empirical approaches and foci that 
all too often rehearse the colonial tropes they ostensibly aim to 
undermine. Collaborations between biomedicine, global health, 
social science, and humanities combining local and global 
contexts, that also engage populations across different nations, will 
help propel a more radical and transformative agenda for global 
public health.
Law
Law and legal processes and their associated institutions are 
present throughout biomedicine, from intellectual property 
regimes to regulation of clinical research to protection of indi-
vidual and collective patients’ rights. All too often, law is per-
ceived to place barriers along the route from science to health; 
for instance, by obstructing research or by creating artificial 
boundaries between different jurisdictions or sectors of research 
(Academy of Medical Sciences, 2011). However, such perceptions 
fail to recognise that law also plays a constitutive role in 
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biomedical research and practice (Cloatre & Pickersgill, 2014). 
This is not least through helping to establish norms and stand-
ards for scientific knowledge production, material and intellec-
tual exchange, constructive participation, and effective ethical 
review that lead to social value (Ganguli-Mitra et al., 2017). For 
instance, regulatory impasse may be overcome through inter-
disciplinary, iterative engagement with scientific communities 
to design and deliver adaptable systems of research governance 
(Laurie et al., 2012).
A deep focus must now be paid to how law functions as an intrin-
sic element of biomedical culture, including its role in the proc-
esses of developing frameworks for pre-emptive regulation that 
enable the emergence and consolidation of socially acceptable 
and accountable biomedical science, as well as in enabling 
the stewardship of biomedical researchers through regulatory 
environments (Laurie et al., 2018). Examining how regulatory 
stakeholders construct legality around their actions and with what 
consequences (Richards, 2015) demands a blending of social 
scientific and humanities insights to understand how regulators 
and regulated actors (including scientists and clinicians) co- 
produce adaptable regulatory practices while raising questions 
about the letter of the law itself (Stephens et al., 2011). Whether, 
where, when, and how law decelerates biomedical development 
and application, or acts as an accelerator of multiple stakeholder-
desired change, demands subtle and careful attention to the 
multiple effects of law and legal processes. Put briefly, we need 
far deeper understandings of law as a lived experience within 
biomedicine than we possess at present.
Science-society engagements
Participation and partnerships are increasingly mobilised in the pro-
duction of biomedical research, the development of health-related 
policy, and health care delivery (Involve, 2005). From individual 
patient involvement through to population-wide engagement, 
multiple sites of participation characterise the nexus between bio-
medicine, healthcare organisations, social groups, and individual 
experiences of health and illness. Politicians, scientists, 
clinicians, and wider publics can have complex relationships 
with the processes, practices, and outcomes of engagements. For 
instance, different forms and instances of engagement can be 
viewed variously as an asset and barrier to policy development, 
health research, and service delivery across clinical and public 
health. Matters are further complicated by the increasing blurring 
of patienthood and participation in (for example) data-intensive 
population studies, where patients become at once producers of 
commercially valuable data as well as consumers of healthcare 
(Prainsack, 2017). Funders and research regulators may also 
intervene to shape the relationship between research, engage-
ment, and participation; for example, by requiring public and 
patient involvement as an essential element of research strategies 
and projects.
Social scientists have led a critical understanding of public 
engagement with respect to science and its governance (Irwin 
& Michael, 2003; Jasanoff, 2003; Kelty & Panofsky, 2014), and 
many have been key to shaping the institutional contexts and 
individual experiences of engagement with biomedicine (Aitken 
et al., 2016; Aitken et al., 2018; Haddow et al., 2007). Parallel 
developments in bioethical thinking have tracked evolving 
paradigms of research ethics and the changing role of par-
ticipants with respect to science (Emanuel & Grady, 2007). 
Understanding and shaping effective participation requires both 
social scientific appreciation of the expertise that non-specialists 
can bring to shaping science and its regulation (Cunningham- 
Burley, 2006; Kerr et al., 2007), and bioethical reflection on how 
best to reconceptualise the normative dimensions of participation 
(Chan & Harris, 2009; Chan et al., 2011). Explorations of how 
publics are currently interpolated within biomedicine, and with 
what consequences, are necessary in their own right (TNS, 
2015). We also have to ask difficult and potentially uncomfort-
able questions about whether, how, and when different groups 
should engage to maximise the public good.
Conclusion
The need to comprehend and interrogate contemporary transfor-
mations in knowledge, health, and experience is vital. Inequalities 
persist despite enormous advances in prevention and treatments; 
new technologies of research and care are troubling accepted 
ideas about the human body, health and disease; and the expan-
sion and proliferation of citizen engagement and partnerships 
bring both opportunities and challenges for biomedical science 
and healthcare. These pressing issues demand imaginative and 
innovative responses. As a considerable body of scholarship 
implies (Cunningham-Burley, 2006; Irwin & Michael, 2003; 
Kerr et al., 2007; Webster, 2002), close engagement between 
diverse communities is required to shape, direct, and, indeed, 
personalise biomedical research in ways that deliver the greatest 
social benefit. Research within and between the medical social 
sciences and humanities is vital. So, too, are novel partner-
ships between scholars in those fields with scientists, clinicians, 
and policy-makers. Researchers across academic disciplines could 
do much more to work effectively together in order to understand 
the complexities inherent in biomedical science, and to promote 
the kinds of social as well as technical change that will deliver 
equitable promotion of health and wellbeing locally, nation-
ally, and globally. They also need to engage enthusiastically, 
deliberatively and openly with wider publics and civic society. 
Ultimately, we need a new social contract between biomedicine 
and society that better serves the aim of improved health and 
well-being for all. If we are to achieve this, it will not be enough 
to challenge one other from the security of our own disciplinary 
perspectives, whichever they are, nor simply to try to reconcile 
our different disciplinary commitments. Together we need to 
rethink biomedicine from the ground up. 
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This is a very thoughtful and timely contribution to the debate on interdisciplinary collaboration in the
health domain. The authors emphasise the important role of "authentic collaborations across and
between the biomedical sciences, humanities and social sciences, and wider society” to create new
knowledge in biomedicine. They then identify and discuss five domains which they argue are of particular
relevance for such collaborations (and particularly impacted by them in turn). 
I consider this Letter a timely and substantive intervention into debates, funding programmes, and policies
shaping knowledge production in this field. In the following section I will share a few thoughts that the
authors may, or may not, take up in their further work on this topic.
Underpinning the argument of the authors is the assumption that relevant biomedical knowledge
can no longer be disciplined into clearly delineated domains of expertise and practice. This is a
profound point that could be made more explicit. What are the reasons for this? The authors
mention “fundamental transformations in the generation and application of knowledge [that]
challenge our understandings and experiences of health, illness, and disease as well as the
organisation of research and care”. But what are these transformations? For example, how are we
to understand the attempts by researchers and policy makers to bring research and healthcare
(e.g. in precision medicine), individual- and population-level data and interventions (e.g. in
precision public health), and the social and the biological (e.g. in epigenetics) closer together?
What types of cross-disciplinary and cross-domain collaborations made this possible, and what
types of collaborations do these new convergences require? 
The names of the five domains that the authors identify - disease, bodies, global movements and
institutions, law, and science-society engagements - are labeled in traditional biomedical and
global health terminology. To reflect the spirit of the cross-domain and cross-disciplinary
collaboration that the authors highlight in their Letter, it may be better to focus not only on disease
but also on illness, not only on bodies but also on people, and on the collaboration between global
and local institutions.
As critical scholars have pointed out, much of the literature conceptualises collaboration as
*transactions* between bounded independent entities. An alternative ontology would be to
conceive collaboration as *interactions* between entities that are related to each other through
shared interests, stakes, (and, in case of human actors, also shared identities). When reading the
Letter I was wondering what ontology underpins the authors’ call for more “authentic" collaboration.
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5.  
Letter I was wondering what ontology underpins the authors’ call for more “authentic" collaboration.
What makes collaborations authentic? What types of actors and relations does authentic
collaboration require? 
The authors’ point, on p4, that “there is a too common tendency to frame financially poorer nations
solely as beneficiaries of healthcare knowledge, as opposed to producers of it” is a very important
one, and one that perhaps deserves even more emphasis and elaboration. How can collaboration
have a positive impact on changing these dominant frames? I also wonder how collecting data
from people in low- and middle income countries (LMIC) would be considered by the authors:
Does this count as healthcare knowledge creation on the side of people in LMIC countries, or does
it increase the new social division between data givers and data takers? Or both?
As a reader of this Letter I would love to hear what the authors consider good examples for the
types of collaborations that they call for. Perhaps it may be possible to name a few examples in the
concluding section, or to give an example in each of the five domains.
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This is a timely and important Open Letter inasmuch as current developments in diverse areas of
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 This is a timely and important Open Letter inasmuch as current developments in diverse areas of
biomedicine, and the life sciences more generally, disturb conventional understandings of the
body/medicine/society relationship. The article rightly points out that as boundaries - of the body, of
disease, of care, of responsibility and so on - become more blurred new forms of  collaboration across the
biomedical sciences, social sciences and humanities is required. New complexities call for new
collaborative endeavour.
The various sections provide very useful, concise overviews of how these disturbances shape different
domains of biomedicine, with a solid body of supportive references to support the argument. Each of
these domains pose specific challenges to biomedicine if it is to be socially robust, that is one that
combines innovation with accountability. The debate in recent years over 'responsible research and
innovation' is clearly of relevance here.
It is then extremely important to show how in practice this interdisciplinary collaboration might be made
possible, and thereby move from a position of critique (key though that is to any engagement) to one of
co-production. Here there is some unevenness in the article, with perhaps most clear recommendations
on what might be involved seen in the concluding observations in the 'Global movements and institutions'
and 'Law' sections. 
To unpack this comment a little more, we can note that in many ways the increasing differentiation of
disease classification systems and the subsequent disruption of the normal/abnormal boundary is to be
welcomed by the social sciences/humanities who have long seen hard borders as problematic (as noted
especially in the section on 'Bodies' in regard to multiple meanings of 'embodiment').  At the same time,
how social science then helps people  - patients/populations/clinicians/biomedical researchers - to create
more valuable and socially robust ways of handling disease and illness becomes an ever greater 
challenge as a result, especially if we are to participate in the co-production of meaning and practice.
Complexity of practices and how these can be managed by patients, clinical staff and carers, for example,
become of central importance (eg in regard to the complexities of end-of-life care). So here social science
needs to address how to handle three interrelated but discrete elements - the complexity of phenomena,
the personal difficulties experienced by people and uncertainty over possible futures.
The challenge for those who take home the very important message of this article is how to find sites
where this form of knowledge is possible and what a new community of practice combining disciplines
would look like. The article concludes by a call to 'rethink biomedicine from the ground up'. Given the
programmatic nature of this piece presumably we need to also rethink social science/humanities 'from the
ground up' too. Perhaps the best place to do this is through identifying trans-disciplinary sites where new
methodologies can be co-created for building a shared understanding, especially when seeking to shape
policy and practice . The challenge in particular is to somehow bridge between what has been called
'critical interdisciplinary research' and 'instrumental interdisciplinary' research  - that is, challenging
conventional understanding in a constructive way.  The authors themselves have shown how this is
possible in their own prior work.  Perhaps an indication of the challenges they faced and how they were
resolved would have helped to point the reader, new to this debate, in the right (interdisciplinary)
direction.
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